Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Our objective was to develop a novel approach to generate individual maps of white matter (WM) innate immune cell activation using 18F-DPA-714 translocator protein PET and to explore the relationship between these maps and individual trajectories of worsening disability in patients with multiple sclerosis (MS). Methods: Patients with MS (n = 37), whose trajectories of worsening disability over the 2 y preceding study entry were calculated, and healthy controls (n = 19) underwent MRI and 18F-DPA-714 PET. A threshold for significant activation of 18F-DPA-714 binding was calculated with a voxelwise randomized permutation-based comparison between patients and controls and used to classify each WM voxel in all subjects as characterized by a significant activation of innate immune cells (DPA+) or not. Individual maps of innate immune cell activation in the WM were used to calculate the extent of activation in WM regions of interests and to classify each WM lesion as DPA-active, DPA-inactive, or unclassified. Results: Compared with the WM of healthy controls, patients with MS had a significantly higher percentage of DPA+ voxels in the normal-appearing WM (NAWM) (NAWM in patients, 24.6% ± 1.4%; WM in controls, 14.6% ± 2.0%; P < 0.001). In patients with MS, the percentage of DPA+ voxels increased significantly from the NAWM to the perilesional areas, T2 hyperintense lesions, and T1 hypointense lesions (38.1% ± 2.6%, 45.0% ± 2.6%, 51.8% ± 2.6%, respectively; P < 0.001). Among the 1,379 T2 lesions identified, 512 were defined as DPA-active and 258 as DPA-inactive. A higher number of lesions classified as DPA-active (odds ratio, 1.13; P = 0.009), a higher percentage of DPA+ voxels in the NAWM (odds ratio, 1.16; P = 0.009), and a higher percentage of DPA+ voxels in T1 spin-echo lesions (odds ratio, 1.06; P = 0.036) were significantly associated with a retrospectively more severe clinical trajectory in patients with MS. Conclusion: A more severe trajectory of disability worsening in MS is associated with innate immune cell activation inside and around WM lesions. 18F-DPA-714 PET may provide a promising biomarker to identify patients at risk of a severe clinical trajectory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Owen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728 · cited 2×
“Our in vivo data also raise the hypothesis that, over the course of the disease, a primary activation of innate immune cells inside some WM lesions that does not subsequently resolve can result in a persistent inflammation that predominates at lesion borders, with or without the persistence of active cells inside the…”
BackgroundThe peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355 · cited 2×
“Our results are in line with postmortem studies showing a substantial innate inflammatory activity within lesions throughout the course of the disease (25).”
BackgroundResultPeferoen, L. A. N., Vogel, D. Y. S., Ummenthum, K., Breur, M., Heijnen, P. D. A. M., Gerritsen, W. H., Peferoen-Baert, R. M. B., van der Valk, P., Dijkstra, C. D., & Amor, S. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000149 · Cited by 178 · cited 1×
“Proinflammatory innate immune cells are involved in active demyelination and axonal damage and have the potential to inhibit myelin repair (3).”
BackgroundRissanen, E., Tuisku, J., Rokka, J., Paavilainen, T., Parkkola, R., Rinne, J. O., & Airas, L. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131698 · Cited by 171 · cited 2×
“Increased binding of 11C-PK11195, the first-generation compound developed for TSPO imaging, has been described inside and outside WM lesions and in the gray matter of patients with all forms of MS (8,9).”
BackgroundResultA quantitative neuropathological assessment of translocator protein expression in multiple sclerosis
Nutma, E., Stephenson, J. A., Gorter, R. P., de Bruin, J., Boucherie, D. M., Donat, C. K., Breur, M., van der Valk, P., Matthews, P. M., Owen, D. R., et al. (2019) · Brain · doi:10.1093/brain/awz287 · Cited by 138 · cited 1×
“A careful interpretation of our results is required with regard to the suboptimal specificity of TSPO tracers, which are known to bind to active innate immune cells but also to astrocytes and endothelial cells (15,28).”
Background
Cited by
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Self-citationPositron emission tomography in multiple sclerosis - straight to the target
Bodini, B., Tonietto, M., Airas, L., & Stankoff, B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00537-1 · Cited by 74
Self-citationRicigliano, V. A. G., Louapre, C., Poirion, E., Colombi, A., Yazdan Panah, A., Lazzarotto, A., Morena, E., Martin, E., Bottlaender, M., Bodini, B., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200026 · Cited by 64
“APHP-20210727144630, EudraCT-Number: 2008-004174-40; ClinicalTrials.gov: NCT02305264, NCT01651520, and NCT02319382.”
MethodSelf-citationMicroglia in multiple sclerosis - pathogenesis and imaging
Airas, L., & Yong, V. W. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001045 · Cited by 52
TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis
Polvinen, E., Matilainen, M., Nylund, M., Sucksdorff, M., & Airas, L. M. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200133 · Cited by 36
Metadata
- Authors
- Bodini, B., Poirion, E., Tonietto, M., Benoit, C., Palladino, R., Maillart, E., Portera, E., Battaglini, M., Bera, G., Kuhnast, B., Louapre, C., Bottlaender, M., & Stankoff, B.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2020-01-31
- Volume
- 61
- Issue
- 7
- Pages
- 1043-1049
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W3003725057
- Cited by
- 40
- References
- 10
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis. https://app.cochat.ai/papers/10.2967/jnumed.119.231340
- The paper
- Bodini, B., Poirion, E., Tonietto, M., Benoit, C., Palladino, R., Maillart, E., Portera, E., Battaglini, M., Bera, G., Kuhnast, B., Louapre, C., Bottlaender, M., & Stankoff, B. (2020). Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.119.231340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.